Asunercept (APG101) is a Selective CD95L Inhibitor for Glioblastoma Research
Glioblastoma is the most frequent and aggressive form of brain tumour. Significantly, the highly invasive growth of these tumors often prevents complete surgical resection. Consequently, patients progress shortly after surgery. In fact, clinical evidence confirms CD95L as a promising novel target for the treatment of recurrent glioblastoma and potentially...
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
In this article, we will introduce a long-acting recombinant human IL-7, Efineptakin alfa. Efineptakin alfa is a potent T-cell amplifier, with a homodimeric IL-7 fused to the hybridizing IgD/IgG4 immunoglobulin domain. Efineptakin alfa supports the proliferation and survival of CD4+ and CD8+ cells in both humans and mice. Patients...
Coibamide A, an Cytotoxic Depsipeptide, Induces Autophagosome Accumulation
Autophagy is the key structure of macroautophagy. Macroautophagy is an intracellular degradation system of cytoplasmic contents. Meanwhile, autophagy is a new double-membrane vesicle formed during autophagy, which can phagocytose a variety of intracellular substances. It transports this autophagic material to the lysosome for subsequent degradation. The lysosomal hydrolase degrades...
FPDT is an anti-glioblastoma agent and shows anti-glioblastoma activity by AKT pathway.
FPDT (2-(4-fluorophenyloamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole) is an anti-glioblastoma agent. FPDT displays cytotoxic with IC50 values of 44-68 μM for GBM cells and >100 μM for human astrocytes HA. Besides, Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway. FPDT (0-100 µM; 48 h) shows anti-proliferative activity with IC50 values of 53.53, 44.98, 55.20, 56.37, 67.73, >100...